PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

Laure Hirsch; Laurence Zitvogel; Alexander Eggermont; Aurelien Marabelle

doi:10.1038/s41416-018-0294-4

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

Laure Hirsch, Laurence Zitvogel, Alexander Eggermont, Aurelien Marabelle

Onderzoeksoutput: Bijdrage aan tijdschrift › Editoriaal

72 Citaten (Scopus)

Samenvatting

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy.

Originele taal-2	Engels
Pagina's (van-tot)	3-5
Aantal pagina's	3
Tijdschrift	British Journal of Cancer
Volume	120
Nummer van het tijdschrift	1
DOI's	https://doi.org/10.1038/s41416-018-0294-4
Status	Gepubliceerd - 8 jan. 2019
Extern gepubliceerd	Ja

Toegang tot document

10.1038/s41416-018-0294-4

Citeer dit

@article{2b1829da59904adabbd592c2309ad2ac,

title = "PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade",

abstract = "Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ({\textquoteleft}PD-Lomas{\textquoteright}) is driving the clinical research strategies for the next generation of combination immunotherapy.",

author = "Laure Hirsch and Laurence Zitvogel and Alexander Eggermont and Aurelien Marabelle",

note = "Publisher Copyright: {\textcopyright} 2018, Cancer Research UK.",

year = "2019",

month = jan,

day = "8",

doi = "10.1038/s41416-018-0294-4",

language = "English",

volume = "120",

pages = "3--5",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - PD-Loma

T2 - a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

AU - Hirsch, Laure

AU - Zitvogel, Laurence

AU - Eggermont, Alexander

AU - Marabelle, Aurelien

PY - 2019/1/8

Y1 - 2019/1/8

N2 - Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy.

AB - Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85056303637&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0294-4

DO - 10.1038/s41416-018-0294-4

M3 - Editorial

C2 - 30413824

AN - SCOPUS:85056303637

SN - 0007-0920

VL - 120

SP - 3

EP - 5

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 1

ER -

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit